

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Biologics, PDE4 Inhibitors), By Route Of Administration (Topical, Injectable, Oral), By Region, And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/AAA730B1A62EN.html

Date: October 2022

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: AAA730B1A62EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Atopic Dermatitis Drugs Market Growth & Trends

The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2022 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is



anticipated to

impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights

In 2021, biologics dominated the market owing to their higher demand and rising biologics approvals

The injectable route of administration segment held the largest share in 2021 and is likely to maintain its dominance throughout the forecast period

Europe is expected to register a significant CAGR in the forecast period owing to factors such as rising awareness among the population about skin conditions such as atopic dermatitis and the presence of a favorable regulatory framework

North America dominated the market in 2021 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region



Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation and Scope
- 1.2 Research Methodology
- 1.3 Information Procurement
 - 1.3.1 Purchased Database
 - 1.3.2 GVR's Internal Database
 - 1.3.3 Secondary Sources
 - 1.3.4 Primary Research
 - 1.3.5 Details of Primary Research
- 1.4 Information or Data Analysis
 - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity Flow Analysis
 - 1.6.1.1 Approach 1: commodity flow approach
- 1.7 List of Secondary Sources
- 1.8 List of Abbreviations
- 1.9 Objectives
 - 1.9.1 Objective
 - 1.9.2 Objective
 - 1.9.3 Objective
 - 1.9.4 Objective

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Summary

CHAPTER 3 ATOPIC DERMATITIS DRUGS MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market Dynamics
 - 3.1.1 Market Driver Analysis
 - 3.1.1.1 Increasing prevalence of atopic dermatitis drugs across the globe
 - 3.1.1.2 Availability of robust product portfolio
 - 3.1.2 Market Restraint Analysis
 - 3.1.2.1 Side-effects Associated with drugs and high cost of these therapeutics



- 3.2 Penetration and Growth Prospect Mapping
- 3.3 Business Environment Analysis Tools
 - 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
 - 3.3.2 Porter's Five Forces Analysis
 - 3.3.3 Industry Analysis Ansoff Matrix
- 3.4 Pricing Analysis
- 3.5 Regulatory Scenario

CHAPTER 4 REGULATORY & POLITICAL FORCES

- 4.1 Recent Developments & Impact Analysis, by Key Market Participants
 - 4.1.1 Heat map analysis
- 4.2 Company Categorization
 - 4.2.1 Innovators
 - 4.2.2 Market Leaders
- 4.3 Vendor Landscape
 - 4.3.1 List of key distributors and channel partners
 - 4.3.2 Key customers
 - 4.3.3 Key company market share analysis, 2021
- 4.4 Public Companies
 - 4.4.1 Company market position analysis
 - 4.4.3.1 Market Differentiators
- 4.5 Private Companies
 - 4.5.1 List of key emerging companies
- 4.6 Major Deals and Strategic Alliances Analysis
 - 4.6.1 New Product Launch
 - 4.6.2 Acquisitions
 - 4.6.3 Expansion
 - 4.6.4 Licensing and Partnerships

CHAPTER 5 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY DRUG CLASS, 2018 - 2030 (USD MILLION)

- 5.1 Drug Class Market Share Analysis, 2021 & 2030 (USD Million)
- 5.2 Segment Dashboard
- 5.3 Market Size & Forecasts and Trend Analysis, 2018 2030 (USD Million)
 - 5.3.1 Corticosteroids
- 5.3.1.1 Corticosteroids Atopic Dermatitis Drugs market estimates and forecast, 2018 -2030 (USD Million)



- 5.3.2 Calcineurin Inhibitors
- 5.3.2.1 Calcineurin Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 2018 2030 (USD Million)
 - 5.3.3 PDE4 Inhibitors
- 5.3.3.1 PDE4 Inhibitors Atopic Dermatitis Drugs market estimates and forecast, 20182030 (USD Million)
- 5.4 Biologics
- 5.4.4.1 Biologics Atopic Dermatitis Drugs market estimates and forecast, 2018 2030 (USD Million)
- 5.5 Others
- 5.5.5.1 Others Atopic Dermatitis Drugs market estimates and forecast, 2018 2030 (USD Million)

CHAPTER 6 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)

- 6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
- 6.2 Segment Dashboard
- 6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
 - 6.3.1 Topical
 - 6.3.1.1 Topical market estimates and forecast, 2018 2030 (USD Million)
 - 6.3.2 Injectable
 - 6.3.2.1 Injectable market estimates and forecast, 2018 2030 (USD Million)
 - 6.3.3 Oral
 - 6.3.3.1 Oral market estimates and forecast, 2018 2030 (USD Million)

CHAPTER 7 ATOPIC DERMATITIS DRUGS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)

- 7.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
- 7.2 Regional Market Dashboard
- 7.3 North America
 - 7.3.1 North America market estimates and forecast, 2018 2030 (USD Million) 7.3.2 U.S.
 - 7.3.2.1 U.S. market estimates and forecast, 2018 2030 (USD Million)
- 7.4 Canada
 - 7.4.1.1 Canada market estimates and forecast, 2018 2030 (USD Million)
- 7.5 Europe
 - 7.5.1 Europe market estimates and forecast, 2018 2030 (USD Million)



7.5.2 Germany

7.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)

7.5.3 U.K.

7.5.3.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)

7.5.4 Spain

7.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)

7.5.5 France

7.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)

7.5.6 Italy

7.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)

7.6 Asia Pacific

7.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)

7.6.2 Japan

7.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)

7.6.3 China

7.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)

7.6.4 India

7.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)

7.6.5 South Korea

7.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)

7.6.6 Australia

7.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)

7.7 Latin America

7.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)

7.7.2 Brazil

7.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)

7.7.3 Mexico

7.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)

7.7.4 Argentina

7.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)

7.8 Middle East & Africa

7.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)

7.8.2 South Africa

7.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)

7.8.3 UAE

7.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)

7.8.4 Saudi Arabia

7.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)



CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE

- 8.1 Participant Categorization
 - 8.1.1 Innovators
 - 8.1.2 Market Leaders
- 8.2 Strategy Mapping
 - 8.2.1 Key Strategies Chosen by Players in this Market include
 - 8.2.1.1 Launch of new products
 - 8.2.1.2 Acquisition
 - 8.2.1.3 Expansion
 - 8.2.1.4 Agreements, collaborations, partnerships
 - 8.2.1.5 Others (realignment, divestment, market penetration)
- 8.3 Strategic Framework
 - 8.3.1 Key Company Market Share Analysis, 2021
- 8.4 Company Profiles
 - 8.4.1 Pfizer Inc.
 - 8.4.1.1 Company overview
 - 8.4.1.2 Financial performance
 - 8.4.1.3 Product benchmarking
 - 8.4.1.4 Strategic initiatives
 - 8.4.2 Sanofi
 - 8.4.2.1 Company overview
 - 8.4.2.2 Financial performance
 - 8.4.2.3 Product benchmarking
 - 8.4.2.4 Strategic initiatives
 - 8.4.3 Regeneron Pharmaceuticals Inc.
 - 8.4.3.1 Company overview
 - 8.4.3.2 Financial performance
 - 8.4.3.3 Product benchmarking
 - 8.4.3.4 Strategic initiatives
 - 8.4.4 LEO Pharma Inc
 - 8.4.4.1 Company overview
 - 8.4.4.2 Financial performance
 - 8.4.4.3 Product pipeline
 - 8.4.4.4 Strategic initiatives
 - 8.4.5 Otsuka Pharmaceutical Co., Ltd.
 - 8.4.5.1 Company overview
 - 8.4.5.2 Financial performance
 - 8.4.5.3 Product pipeline



- 8.4.5.4 Strategic initiatives
- 8.4.6 AbbVie Inc.
 - 8.4.6.1 Company overview
 - 8.4.6.2 Product benchmarking
 - 8.4.6.3 Strategic initiatives
- 8.4.7 GALDERMA LABORATORIES, L.P.
 - 8.4.7.1 Company overview
 - 8.4.7.2 Financial performance
 - 8.4.7.3 Product benchmarking
 - 8.4.7.4 Strategic initiatives
- 8.4.8 Dermira, Inc. (Eli Lilly and Company)
 - 8.4.8.1 Company overview
 - 8.4.8.2 Financial performance
 - 8.4.8.3 Product benchmarking
- 8.4.8.4 Strategic initiatives
- 8.4.9 Novartis AG
 - 8.4.9.1 Company overview
 - 8.4.9.2 Financial performance
 - 8.4.9.3 Product benchmarking
 - 8.4.9.4 Strategic initiatives
- 8.4.10 Incyte Corporation
 - 8.4.10.1 Company overview
 - 8.4.10.2 Financial performance
 - 8.4.10.3 Product benchmarking
 - 8.4.10.4 Strategic initiatives



List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviations

Table 3 North America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)

Table 4 North America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 5 North America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 6 U.S. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 7 U.S. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 8 Canada Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 9 Canada Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 10 Europe Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)

Table 11 Europe Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 12 Europe Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 13 U.K. Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 14 U.K. Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 15 Germany Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 16 Germany Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 17 France Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 18 France Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 19 Spain Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)



Table 20 Spain Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 21 Italy Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 22 Italy Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 23 Asia Pacific Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)

Table 24 Asia Pacific Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 25 Asia Pacific Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 26 Japan Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 27 Japan Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)

Table 28 China Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 29 China Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 30 India Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 31 India Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 32 South Korea Atopic Dermatitis Drugs Market, By Drug Class2018 - 2030 (USD Million)

Table 33 South Korea Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)

Table 34 Australia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 35 Australia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 36 Latin America Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)

Table 37 Latin America Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 38 Latin America Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 39 Brazil Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD



Million)

Table 40 Brazil Atopic Dermatitis Drugs Market, By Route of Administration 2018 - 2030 (USD Million)

Table 41 Mexico Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 42 Mexico Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 43 Argentina Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 44 Argentina Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 45 Middle East & Africa Atopic Dermatitis Drugs Market, By Country, 2018 - 2030 (USD Million)

Table 46 Middle East & Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 47 Middle East & Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 48 South Africa Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 49 South Africa Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 50 Saudi Arabia Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 51 Saudi Arabia Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 52 UAE Atopic Dermatitis Drugs Market, By Drug Class, 2018 - 2030 (USD Million)

Table 53 UAE Atopic Dermatitis Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)



List Of Figures

LIST OF FIGURES

- Fig. 1 Atopic dermatitis drugs market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Atopic dermatitis drugs market snapshot
- Fig. 10 Atopic dermatitis drugs market driver impact
- Fig. 11 Atopic dermatitis drugs market restraint impact
- Fig. 12 Penetration and growth prospect mapping
- Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
- Fig. 14 Porter's five forces analysis
- Fig. 15 Ansoff matrix
- Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
- Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
- Fig. 18 Drug class segment dashboard
- Fig. 19 Corticosteroids atopic dermatitis drugs market estimates and forecast, 2018 2030 (USD Million)
- Fig. 20 Calcineurin inhibitors atopic dermatitis drugs market estimates and forecast,
- 2018 2030 (USD Million)
- Fig. 21 PDE4 inhibitors atopic dermatitis drugs market estimates and forecast, 2018 2030 (USD Million)
- Fig. 22 Biologics atopic dermatitis drugs market estimates and forecast, 2018 2030 (USD Million)
- Fig. 23 Others atopic dermatitis drugs market estimates and forecast, 2018 2030 (USD Million)
- Fig. 24 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
- Fig. 25 Atopic dermatitis drugs market: Route of administration analysis
- Fig. 26 Route of administration dashboard
- Fig. 27 Topical market estimates and forecast, 2018 2030 (USD Million)
- Fig. 28 Injectable market estimates and forecast, 2018 2030 (USD Million)
- Fig. 29 Oral infections market estimates and forecast, 2018 2030 (USD Million)



- Fig. 30 Atopic dermatitis drugs market: regional outlook and key takeaways
- Fig. 31 Regional outlook, 2021 & 2030 (USD Million)
- Fig. 32 Regional market dashboard
- Fig. 33 North America
- Fig. 34 North America market estimates and forecast, 2018 2030 (USD Million)
- Fig. 35 U.S.
- Fig. 36 U.S. market estimates and forecast, 2018 2030 (USD Million)
- Fig. 37 Canada
- Fig. 38 Canada market estimates and forecast, 2018 2030 (USD Million)
- Fig. 39 Europe
- Fig. 40 Europe market estimates and forecast, 2018 2030 (USD Million)
- Fig. 41 Germany
- Fig. 42 Germany market estimates and forecast, 2018 2030 (USD Million)
- Fig. 43 U.K.
- Fig. 44 U.K. market estimates and forecast, 2018 2030 (USD Million)
- Fig. 45 Spain
- Fig. 46 Spain market estimates and forecast, 2018 2030 (USD Million)
- Fig. 47 France
- Fig. 48 France market estimates and forecast, 2018 2030 (USD Million)
- Fig. 49 Italy
- Fig. 50 Italy market estimates and forecast, 2018 2030 (USD Million)
- Fig. 51 Asia Pacific
- Fig. 52 Asia Pacific market estimates and forecast, 2018 2030 (USD Million)
- Fig. 53 Japan
- Fig. 54 Japan market estimates and forecast, 2018 2030 (USD Million)
- Fig. 55 China
- Fig. 56 China market estimates and forecast, 2018 2030 (USD Million)
- Fig. 57 India
- Fig. 58 India market estimates and forecast, 2018 2030 (USD Million)
- Fig. 59 South Korea
- Fig. 60 South Korea market estimates and forecast, 2018 2030 (USD Million)
- Fig. 61 Australia
- Fig. 62 Australia market estimates and forecast, 2018 2030 (USD Million)
- Fig. 63 Latin America
- Fig. 64 Latin America market estimates and forecast, 2018 2030 (USD Million)
- Fig. 65 Brazil
- Fig. 66 Brazil market estimates and forecast, 2018 2030 (USD Million)
- Fig. 67 Mexico
- Fig. 68 Mexico market estimates and forecast, 2018 2030 (USD Million)



- Fig. 69 Argentina
- Fig. 70 Argentina market estimates and forecast, 2018 2030 (USD Million)
- Fig. 71 Middle East & Africa
- Fig. 72 Middle East & Africa market estimates and forecast, 2018 2030 (USD Million)
- Fig. 73 South Africa
- Fig. 74 South Africa market estimates and forecast, 2018 2030 (USD Million)
- Fig. 75 UAE
- Fig. 76 UAE market estimates and forecast, 2018 2030 (USD Million)
- Fig. 77 Saudi Arabia
- Fig. 78 Saudi Arabia market estimates and forecast, 2018 2030 (USD Million)
- Fig. 79 Participant categorization
- Fig. 80 Strategy mapping
- Fig. 81 Strategic framework
- Fig. 82 Company market share analysis



I would like to order

Product name: Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class

(Biologics, PDE4 Inhibitors), By Route Of Administration (Topical, Injectable, Oral), By

Region, And Segment Forecasts, 2022 - 2030

Product link: https://marketpublishers.com/r/AAA730B1A62EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/AAA730B1A62EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970